Filing Flows › Camp4 Therapeutics (CAMP) › Guidance & outlook
Camp4 Therapeutics (CAMP) guidance and outlook
Camp4 Therapeutics' 10-Q filed Nov 5, 2026 makes 26 forward-looking statements.
Guidance and outlook
Forward-looking statements, 10-Q filed Nov 5, 2026
- We are a clinical-stage biopharmaceutical company pioneering the discovery and development of a new class of RNA-targeting therapeutics with the goal of upregulating gene expression and restoring healthy protein levels to treat a broad range of genetic diseases.
- While we believe that it remains underdiagnosed, we estimate that there are approximately 21,000 individuals living with SYNGAP1 in the United States and the five largest European markets.
- We expect to dose the first patient in the ASCEND Phase 1/2 clinical trial in the fourth quarter of 2026.
- In addition to our SYNGAP1 program, we are advancing a preclinical program targeting SHANK3 for Phelan-McDermid syndrome, a neurodevelopmental disorder characterized by autism, developmental delay, intellectual disability, motor impairment and milestone regression, for which there are no approved disease-modifying treatments.
- We estimate that there are more than 45,000 patients with Phelan-McDermid syndrome in the United States.
- We expect to designate a development candidate in the SHANK3 program in 2027.
- Additionally, we intend to leverage strategic discovery partnerships, including our research, collaboration, and license agreement with GlaxoSmithKline Intellectual Property (No.3) Limited ("GSK"), to extend the application of our RAP Platform beyond the CNS and validate our approach to gene upregulation in additional tissues and disease areas.
- Once a disease-associated target gene is identified, we apply our RAP Platform to identify the controlling regRNA and rapidly generate novel ASO candidates.
- If we obtain regulatory approval for our product candidates, we expect to incur significant expenses related to developing our commercialization capability to support product sales, marketing and distribution.
- We anticipate that our expenses will increase substantially if and as we:
- Because of the numerous risks and uncertainties associated with the development of therapeutics, we are unable to accurately predict the timing or amount of increased expenses and when, or if, we will be able to achieve or maintain profitability.
- We will not generate revenue from product sales unless and until we successfully complete clinical development and obtain regulatory approval for our current or any future product candidates, which we expect will take a number of years or may never occur.
Camp4 Therapeutics' latest quarter
Camp4 Therapeutics, Q3 2026: revenue $1.9M (+139% year over year), operating margin -738.8%, net loss $29.0M, operating cash flow −$8.2M. The chart follows the revenue to costs, profit and cash.
Questions
What does Camp4 Therapeutics expect?
We are a clinical-stage biopharmaceutical company pioneering the discovery and development of a new class of RNA-targeting therapeutics with the goal of upregulating gene expression and restoring healthy protein levels to treat a broad range of genetic diseases. While we believe that it remains underdiagnosed, we estimate that there are approximately 21,000 individuals living with SYNGAP1 in the United States and the five largest European markets. We expect to dose the first patient in the ASCEND Phase 1/2 clinical trial in the fourth quarter of 2026.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.